NO20023402D0 - Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft - Google Patents

Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft

Info

Publication number
NO20023402D0
NO20023402D0 NO20023402A NO20023402A NO20023402D0 NO 20023402 D0 NO20023402 D0 NO 20023402D0 NO 20023402 A NO20023402 A NO 20023402A NO 20023402 A NO20023402 A NO 20023402A NO 20023402 D0 NO20023402 D0 NO 20023402D0
Authority
NO
Norway
Prior art keywords
diagnosis
mixtures
treatment
methods
prostate cancer
Prior art date
Application number
NO20023402A
Other languages
English (en)
Other versions
NO20023402L (no
Inventor
Jiangchun Xu
Davin C Dillon
Jennifer Lynn Mitcham
Susan L Harlocker
Yuqiu Jiang
Steven G Reed
Michael D Kalos
Gary Richard Fanger
Craig H Day
Marc W Retter
John A Stolk
Yasir A W Skeiky
Aijun Wang
Madeleine Joy Meagher
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of NO20023402D0 publication Critical patent/NO20023402D0/no
Publication of NO20023402L publication Critical patent/NO20023402L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4275—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20023402A 2000-01-14 2002-07-15 Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft NO20023402L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48367200A 2000-01-14 2000-01-14
PCT/US2001/001574 WO2001051633A2 (en) 2000-01-14 2001-01-16 Compositions and methods for the therapy and diagnosis of prostate cancer

Publications (2)

Publication Number Publication Date
NO20023402D0 true NO20023402D0 (no) 2002-07-15
NO20023402L NO20023402L (no) 2002-08-29

Family

ID=23921037

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023402A NO20023402L (no) 2000-01-14 2002-07-15 Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft

Country Status (16)

Country Link
EP (1) EP1261708A2 (no)
JP (1) JP2003528591A (no)
KR (1) KR20030016217A (no)
CN (1) CN1436234A (no)
AU (1) AU3447401A (no)
BR (1) BR0107643A (no)
CA (1) CA2397741A1 (no)
CZ (1) CZ20022756A3 (no)
HU (1) HUP0203968A3 (no)
IL (1) IL150732A0 (no)
MX (1) MXPA02006934A (no)
NO (1) NO20023402L (no)
PL (1) PL356908A1 (no)
RU (1) RU2002121771A (no)
WO (1) WO2001051633A2 (no)
ZA (1) ZA200206400B (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
AU7019498A (en) 1997-04-10 1998-10-30 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US6861215B1 (en) 1998-05-21 2005-03-01 Diadexus, Inc. Method of diagnosing, monitoring, and staging prostate cancer
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DE69941187D1 (de) 1998-06-01 2009-09-10 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US7083796B2 (en) 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US7022497B1 (en) 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
JP2003510075A (ja) 1999-09-29 2003-03-18 ディグノキュアー・インコーポレーテッド 良性および悪性の前立腺組織におけるｐｃａ３メッセンジャーｒｎａ種
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
DK1517913T3 (da) * 1999-10-07 2007-06-18 Corixa Corp En Mycobacterium tuberculosis-kodende sekvens til ekspression af heterologe proteiner
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
AU2001249549A1 (en) * 2000-03-27 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002006537A2 (en) * 2000-07-13 2002-01-24 Curagen Corporation Methods of identifying renal protective factors
ATE396266T1 (de) * 2000-07-28 2008-06-15 Ulrich Wissenbach Trp8 krebsmarker
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
JP2005504513A (ja) * 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
KR100788092B1 (ko) * 2001-06-20 2007-12-21 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1474516B1 (en) 2002-01-25 2013-03-27 The Regents of The University of California Methods of modulating cold sensory perception
DE10215321A1 (de) * 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh Trp-p8 Splice Varianten und regulatorische RNA
KR20050010040A (ko) * 2002-06-11 2005-01-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
DE10234901A1 (de) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004070056A2 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
NZ550816A (en) 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
KR20080016955A (ko) * 2005-06-14 2008-02-22 디나벡크 가부시키가이샤 항체의 제작방법
MX2009003938A (es) 2006-10-27 2009-04-24 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
HUE064187T2 (hu) * 2012-05-25 2024-02-28 Cellectis Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására
CN104357451B (zh) * 2014-12-02 2016-09-21 广州市番禺区中心医院 针对dd3基因的小干扰rna及其表达载体构建与应用
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520566D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
PT3558339T (pt) * 2016-12-22 2024-03-15 Cue Biopharma Inc Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos
AU2018247767B2 (en) 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
CN110988348B (zh) * 2019-11-06 2022-07-05 北京九强生物技术股份有限公司 游离前列腺特异性抗原检测试剂盒及其制备方法
WO2022015694A1 (en) * 2020-07-13 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii–restricted drb t cell receptors against ras with g12d mutation
CN114250238B (zh) * 2021-11-26 2023-08-25 北京航空航天大学 基因编码的神经元发育调控多肽及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990087802A (ko) * 1996-03-15 1999-12-27 길리스 스티브 전립선암의 면역치료 및 면역진단을 위한 화합물 및 방법
AR012035A1 (es) * 1997-02-25 2000-09-27 Corixa Corp Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico
CA2281952C (en) * 1997-02-25 2011-07-19 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
AU762812B2 (en) * 1998-07-14 2003-07-03 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
JP2004537252A (ja) * 1999-11-12 2004-12-16 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法

Also Published As

Publication number Publication date
BR0107643A (pt) 2003-06-10
HUP0203968A3 (en) 2004-09-28
JP2003528591A (ja) 2003-09-30
AU3447401A (en) 2001-07-24
PL356908A1 (en) 2004-07-12
ZA200206400B (en) 2004-01-21
WO2001051633A9 (en) 2002-10-31
WO2001051633A3 (en) 2002-06-20
CA2397741A1 (en) 2001-07-19
IL150732A0 (en) 2003-02-12
CZ20022756A3 (cs) 2003-02-12
RU2002121771A (ru) 2004-03-10
NO20023402L (no) 2002-08-29
EP1261708A2 (en) 2002-12-04
WO2001051633A2 (en) 2001-07-19
CN1436234A (zh) 2003-08-13
KR20030016217A (ko) 2003-02-26
HUP0203968A2 (hu) 2003-03-28
MXPA02006934A (es) 2003-01-28

Similar Documents

Publication Publication Date Title
NO20023402D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft
NO20030714D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av HER-2/NEU-assosierte maligniteter
NO20013002D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av ovariekreft
NO20024972D0 (no) Blandinger og fremgangsmåter for terapi og diagnose av brystkreft
NO20010196L (no) Sammensetninger og fremgangsmÕter for terapi og diagnose av prostatakreft
NO20016427D0 (no) Blandinger og fremgangsmåter for behandling av diagnose av lungekreft
NO20014769D0 (no) Preparat for behandling og diagnose av bryst cancer og fremgangsmåter for anvendelse derav
NO983183L (no) Blandinger og fremgangsmåte for behandling og diagnose av brystkreft
NO20003853L (no) Forbindelser for terapi og diagnose av lungekreft og metoder for deres anvendelse
DK1587837T3 (da) Epitopsekvenser til diagnose og behandling af prostatacancer
NO20022592D0 (no) Forbindelser og fremgangsmåter for behandling og diagnose av Chlamydia-infeksjoner
ITMI990375A1 (it) Trattamento del cancro co epotiloni
EP1515982A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
NO20043246L (no) Nye fremgangsmater til diagnose og behandling av tumorer
NO20032395L (no) Ekspresjonsanalyse av FKBP-nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft
NO994932D0 (no) Blandinger og fremgangsmaater for behandling og diagnose av brystkreft
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
AU2002246519A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
EP1320376A4 (en) TREATMENT OF PROSTATE CANCER
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
NO20014804D0 (no) Forbindelser for immunterapi og diagnose av brystkreft og fremgangsmåter for deres anvendelse
NO20025594D0 (no) Blandinger og fremgangsmåter for terapi og diagnose av brystkreft
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
EP1349485A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application